SEATTLE — The number of initial monthly aflibercept injections may play a role in achieving optimal visual outcomes in diabetic macular edema, according to a study presented at the American Society of Retina Specialists annual meeting.
Ferhina S. Ali, MD, MPH, said patients with DME can be undertreated, and studies have shown an association between the number of initial monthly injections and visual acuity improvement.
“Our goal here was to evaluate the factors associated with initial monthly dosing of aflibercept and the impact on visual and anatomic outcomes at 12 months,”